Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Prurigo Nodularis
NCT06516965Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of povorcitinib in prurigo nodularis (PN), sponsored by Incyte. Started Oct 2024; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06516965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516965.